371pa Multicenter Phase Ii Trial of Nab-paclitaxel in Combination with Capecitabine in Patients (pts) with Her-2 Negative and Triple Negative Advanced Breast Cancer (abc): an Interim Analysis.

نویسندگان

  • M Ciccarese
  • L Orlando
  • P Fedele
  • P Schiavone
  • E Maiello
  • P Cilenti
  • M Aieta
  • G Bozza
  • M R C Forcignanò
  • A Febbraro
  • R Bordonaro
  • S Romito
  • A Rinaldi
  • N Borsellino
  • F Riccardi
  • S Pisconti
  • V Lorusso
  • G Colucci
  • S Cinieri
چکیده

M. Ciccarese1, L. Orlando2, P. Fedele3, P. Schiavone2, E. Maiello4, P. Cilenti5, M. Aieta6, G. Bozza6, M.R.C. Forcignanò1, A. Febbraro7, R. Bordonaro8, S. Romito9, A. Rinaldi10, N. Borsellino11, F. Riccardi12, S. Pisconti13, V. Lorusso14, G. Colucci15, S. Cinieri16 Oncology Dept., Ospedale Vito Fazzi, Lecce, ITALY Ospedale Perrino, Oncologia Brindisi, Brindisi, ITALY Oncology & Breast Unit, Antonio Perrino Hospital, Brindisi, ITALY Oncology, Casa Sollievo della Sofferenza, S. Giovanni Rotondo, ITALY Oncology Dept., Casa Sollievo della Sofferenza, S. Giovanni Rotondo, ITALY Medical Oncology, Department of Medical Oncology, National Institute of Cancer, Rionero in Vulture (PZ)., Rionero (PZ), ITALY Oncology, Ospedale Fatebenefratelli Benevento, Benevento, ITALY Oncology, “Garibaldi Nesima Superiore” Hospital, Catania, ITALY Onco-ematologia Universitaria, Ospedale Riuniti di Foggia, Foggia, ITALY Oncology, Presidio Ospedaliero Occidentale, Castellaneta, ITALY Oncology, “Buccheri la Ferla Fatebenefratelli” Hospital, Palermo, ITALY Oncology, Ospedale Cardarelli, Naples, ITALY Oncology, “S.G. Moscati” Hospital, Taranto, ITALY Oncology, “Giovanni Paolo II” IRCCS, Bari, ITALY Medical and Experimental Oncology Unit, Cancer Institute Giovanni Paolo II, Bari, ITALY Oncology, “Sen. Perrino” Hospital, Brindisi, ITALY

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Phase II/III weekly nab-paclitaxel plus gemcitabine or carboplatin versus gemcitabine/carboplatin as first-line treatment of patients with metastatic triple-negative breast cancer (the tnAcity study): study protocol for a randomized controlled trial.

BACKGROUND Triple-negative breast cancer is an aggressive disease with unmet clinical needs. In a phase III study of patients with metastatic triple-negative breast cancer, first-line gemcitabine/carboplatin resulted in a median progression-free survival of 4.6 months. nab-paclitaxel-based regimens (with gemcitabine or carboplatin±bevacizumab) also demonstrated efficacy and safety in first-line...

متن کامل

Cancer Therapy: Clinical TBCRC 019: A Phase II Trial of Nanoparticle Albumin-Bound Paclitaxel with or without the Anti-Death Receptor 5 Monoclonal Antibody Tigatuzumab in Patients with Triple-Negative Breast Cancer

Purpose: Tigatuzumab (TIG), an agonistic anti-DR5 antibody, triggers apoptosis in DR5þ human tumor cells without crosslinking. TIG has strong in vitro/in vivo activity against basal-like breast cancer cells enhanced by chemotherapy agents. This study evaluates activity of TIG and chemotherapy in patients with metastatic triple-negative breast cancer (TNBC). Experimental Design: Randomized 2:1 p...

متن کامل

Phase II trial of weekly nab-paclitaxel and carboplatin treatment with or without trastuzumab as nonanthracycline neoadjuvant chemotherapy for locally advanced breast cancer

BACKGROUND Neoadjuvant chemotherapy has become standard treatment for women with locally advanced breast cancer. The aim of this study was to compare the efficacy and safety of nanoparticle albumin-bound paclitaxel (nab-paclitaxel) versus paclitaxel combined with carboplatin. METHODS Thirty patients were treated with neoadjuvant nab-paclitaxel (125 mg/m(2), days 1, 8, and 15) and carboplatin ...

متن کامل

A randomized phase I trial of nanoparticle albumin-bound paclitaxel with or without mifepristone for advanced breast cancer

PURPOSE Glucocorticoid receptor (GR) overexpression is associated with poor prognosis ER-negative breast cancer. GR antagonism with mifepristone increases chemotherapy-induced breast cancer cell death, therefore we conducted a phase I clinical trial of mifepristone and nab-paclitaxel in advanced breast cancer. METHODS A novel randomized phase I design was used to assess the effect of mifepris...

متن کامل

Long-Term Complete Remission with nab-Paclitaxel, Bevacizumab, and Gemcitabine Combination Therapy in a Patient with Triple-Negative Metastatic Breast Cancer

This is a case study of a 52-year-old female patient diagnosed in June 2007 with primary metastatic invasive ductal carcinoma of the left breast and synchronous metastases in the bone, lymph nodes, and lung. Biopsy results of the tumor tissue were negative for the estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 (HER2). In November 2007, she participated in...

متن کامل

ذخیره در منابع من

ذخیره در منابع من قبلا به منابع من ذحیره شده

{@ msg_add @}


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

عنوان ژورنال:
  • Annals of oncology : official journal of the European Society for Medical Oncology

دوره 25 suppl_4  شماره 

صفحات  -

تاریخ انتشار 2014